Brain and Central Nervous System Tumors Clinical Trial
Official title:
A Cancer Research UK Phase I Trial of IMA950 (A Novel Multi-Peptide Vaccine) Plus GM-CSF in Patients With Newly Diagnosed Glioblastoma
RATIONALE: Vaccines made from peptides may help the body build an effective immune response
to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving vaccine
therapy together with temozolomide and radiation therapy may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects of vaccine therapy when given
together with temozolomide and radiation therapy in treating patients with newly diagnosed
glioblastoma multiforme.
OBJECTIVES:
Primary
- To assess the safety and tolerability of glioblastoma multiform multi-antigen vaccine
IMA950 plus sargramostim (GM-CSF) in combination with standard chemoradiotherapy
comprising temozolomide and radiotherapy followed by adjuvant temozolomide in patients
with newly diagnosed glioblastoma multiforme.
- To determine the immunogenicity of this regimen in these patients.
Secondary
- To determine the anti-tumor effect of this regimen in these patients.
- To determine the effect of pre-treatment levels of regulatory T-cells on the
immunogenicity of this regimen in these patients. (Exploratory)
- To evaluate the potential effect of steroid dose on the immunological response to
glioblastoma multiform multi-antigen vaccine IMA950 plus GM-CSF.
Tertiary
- To assess the level of O6-methyl-DNA-methyltransferase (MGMT) promoter methylation in
tumor tissue and any potential association with any observed anti-tumor effect.
- To evaluate the kinetics of the observed immunogenicity of glioblastoma multiform
multi-antigen vaccine IMA950 plus GM-CSF.
- To explore the possible biomarker signatures that may predict immunological response to
glioblastoma multiform multi-antigen vaccine IMA950 plus GM-CSF. (Exploratory)
- To explore the possible effects of this regimen on any observed pseudo-progression and
pseudo-regression in these patients. (exploratory)
OUTLINE: This is a multicenter study. Patients are recruited to cohort 1 or 2 with priority
recruitment to cohort 1. All patients undergo standard chemoradiotherapy followed by
adjuvant temozolomide as planned.
- Standard therapy (chemoradiotherapy and adjuvant temozolomide): Beginning after
surgery, patients receive chemoradiotherapy comprising oral temozolomide daily for 6
weeks and radiotherapy once daily, 5 days a week for 6 weeks. Beginning 35 days after
completion of radiotherapy, patients receive adjuvant oral temozolomide alone on days
1-5. Treatment with temozolomide repeats every 28 days for 6 courses.
- Vaccine therapy: Patients also receive vaccine therapy beginning at one of two time
points. Patients are recruited into 1 of 2 cohorts that differ in the timing of the
vaccination schedule in relation to a patient's standard therapy.
- Cohort 1: Vaccination begins 7-14 days prior to chemoradiotherapy.
- Induction phase: Patients receive the first 6 doses of sargramostim
intradermally (ID) followed by glioblastoma multiform multi-antigen vaccine
IMA950 ID on days 1, 2, 3, 8, 15, and 22 in the absence of disease
progression or unacceptable toxicity.
- Maintenance phase: Patients receive sargramostim followed by glioblastoma
multiform multi-antigen vaccine IMA950 ID on days 50 and 78 and then on day
21 of each adjuvant temozolomide course, beginning in course 1, for 3 courses
in the absence of disease progression or unacceptable toxicity.
- Cohort 2: Vaccination begins at least 7 days after chemoradiotherapy and 28 days
prior to adjuvant temozolomide.
- Induction phase: Patients receive the first 6 doses of sargramostim followed
by glioblastoma multiform multi-antigen vaccine IMA950 ID as in cohort 1
induction phase, beginning at a different time point.
- Maintenance phase: Patients receive sargramostim followed by glioblastoma
multiform multi-antigen vaccine IMA950 ID on day 21 of each adjuvant
temozolomide course, beginning in course 1, for 5 courses in the absence of
disease progression or unacceptable toxicity.
Blood samples are collected periodically for pharmacodynamic, biomarker, and immunologic
studies.
After completion of study treatment, patients are followed at 41 weeks.
Peer Reviewed and Funded or Endorsed by Cancer Research UK
;
Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00006080 -
Fenretinide in Treating Patients With Recurrent Malignant Glioma
|
Phase 2 | |
Recruiting |
NCT00887146 -
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
|
Phase 3 | |
Suspended |
NCT00935090 -
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
|
N/A | |
Completed |
NCT00621686 -
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00112502 -
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT00227032 -
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
|
Phase 1 | |
Terminated |
NCT00243022 -
Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme
|
Phase 2 | |
Active, not recruiting |
NCT00087815 -
Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain
|
N/A | |
Active, not recruiting |
NCT00278278 -
Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas
|
Phase 3 | |
Completed |
NCT00416819 -
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
|
N/A | |
Completed |
NCT00052286 -
Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer
|
N/A | |
Completed |
NCT00006093 -
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
|
Phase 1/Phase 2 | |
Recruiting |
NCT00004129 -
Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00004212 -
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT00003417 -
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
Completed |
NCT00008008 -
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
|
Phase 2 | |
Completed |
NCT00003173 -
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
|
Phase 2 | |
Completed |
NCT00003484 -
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
|
Phase 1 | |
Completed |
NCT00003464 -
Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme
|
Phase 2 |